ScienceOpen:
research and publishing network
For Publishers
Discovery
Metadata
Peer review
Hosting
Publishing
For Researchers
Join
Publish
Review
Collect
My ScienceOpen
Sign in
Register
Dashboard
Blog
About
Search
Advanced search
My ScienceOpen
Sign in
Register
Dashboard
Search
Search
Advanced search
For Publishers
Discovery
Metadata
Peer review
Hosting
Publishing
For Researchers
Join
Publish
Review
Collect
Blog
About
4
views
0
references
Top references
cited by
2
0 reviews
Review
0
comments
Comment
0
recommends
+1
Recommend
0
collections
Add to
0
shares
Share
Twitter
Sina Weibo
Facebook
Email
2,026
similar
All similar
Record
: found
Abstract
: not found
Article
: not found
KEYNOTE-189: OS Update and Progression After the Next Line of Therapy (PFS2) with Pembrolizumab plus Chemotherapy for Metastatic Nonsquamous NSCLC.
Author(s):
S. Gadgeel
,
MC Garassino
,
E Esteban
,
M.C. Garassino
,
G Speranza
,
E Felip
,
M.J. Hochmair
,
S. POWELL
,
S.Y.-S. Cheng
,
H.G. Bischoff
,
N PELED
,
R Hui
,
M Reck
,
T. Kurata
,
E.B. Garon
,
M. BOYER
,
J. Yang
,
M.C. Pietanza
,
D Rodríguez-Abreu
Publication date:
2019
Journal:
J Thorac Oncol
Read this article at
ScienceOpen
Publisher
Further versions
open (via crossref license)
Powered by
Bookmark
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Related collections
Embodied Memory
Author and article information
Journal
DOI::
10.1016/j.jtho.2019.09.090
Data availability:
Comments
Comment on this article
Sign in to comment
scite_
Similar content
2,026
Statistical analysis of episensitization using transition probability functions and PFS2 for “ROCKET”, a two stage phase II study of RRx-001, a multi-epigenetic agent, investigating resensitization to irinotecan in colorectal cancer
Authors:
N Abrouk
,
TR Reid
,
GA Fisher
Inactivation of the pre-mRNA cleavage and polyadenylation factor Pfs2 in fission yeast causes lethal cell cycle defects.
Authors:
Chris Norbury
,
Takashi Toda
,
Shao L. Wang
…
Updated analysis of progression‐free survival with first subsequent therapy (PFS2) and safety in the SPARTAN study of apalutamide (APA) in patients (pts) with high‐risk nonmetastatic castration‐resistant prostate cancer (nmCRPC)
Authors:
EJ Small
,
F. SAAD
,
S CHOWDHURY
…
See all similar
Cited by
2
The validity of progression‐free survival 2 as a surrogate trial end point for overall survival
Authors:
Rachel G Woodford
,
Deborah Zhou
,
Peey-Sei Kok
…
The clinical outcome and risk factors analysis of immune checkpoint inhibitor-based treatment in lung adenocarcinoma patients with brain metastases
Authors:
Juan Zhou
,
Yinfei Wu
,
Mengqing Xie
…
See all cited by